Abstract
Objective(s):
Leishmaniasis is endemic in 88 countries. Amastigote forms of Leishmania are experts at exploiting host cell processes to establish infection. Monoclonal antibodies are key reagents used in the diagnosis of infectious and non-infectious diseases. The aim of this study was to produce monoclonal antibodies against axenic amastigotes of the Leishmania infantum strain in Iran.
Materials and Methods:
First, standard strains were cultured and axenic amastigote antigens of L. infantum were obtained. Since then, BALB/c smice were immunized and antibody titers were determined. For hybridoma cell formation, lymphocytes isolated from spleen of immunized mice and myeloma cells were fused at a ratio of 10 to 1 in the presence of polyethylene glycol, followed by limiting dilution for the isolation of monoclones. Subsequently, antibody isotypes were determined by using the isotyping kit. The best clone was injected intraperitoneally to pristane-primed mice for large scale production of monoclonal antibodies. The specificity of antibody was determined with Western blotting.
Results:
Approximately 25 positive monoclones were obtained, of which four hybrids producing anti-amastigotes L. infantum monoclonal antibodies with high optical density (OD), selected and designated as 8D2 FVI6, 8D2 FVI3, 6G2 FV4 and 6G2 FV3. Results from isotype determination showed the IgG2b sub-class in 6G2FV2 and 8D2FVI6 monoclones.
Conclusion:
This study produced monoclonal antibody against amastigotes of Iranian strain of L. infantum for the first time. These antibodies have reactivity against Iranian strain of L. infantum and can be used in the diagnosis of Kala-azar.
Keywords: Axenic amastigotes, Hybridoma cells, Leishmaniases, Leishmania infantum, Monoclonal antibodies
Introdction
Although in recent years identifying of Leishmania species using molecular methods such as PCR-RFLP and kDNA-PCR is performed in some research centers, these methods could not meet the needs of common laboratories and health programs because they are expensive and require special equipment. In addition, because of high level of polymorphisms in different species of Leishmania, these methods are not applicable in most of ordinary laboratories. It seems that mAbs usage is more appropriate to diagnose leishmaniases, specially it should be mentioned that the specificity of procedure using monoclonal antibodies are higher than other procedures (1).
Leishmaniasis is widely distributed around the world and is greatly important for humans as a leading cause of serious infectious diseases. Leishmaniasis is one of the most important contagious diseases caused by parasites of the genus Leishmania, a common parasite throughout the world and Iran. Although many efforts have been made to control the disease, leishmaniasis is still one of the health problems in the world (2-5).
Three forms of this disease have been identified in humans in which visceral leishmaniasis is the most threatening form; visceral leishmaniasis is endemic in 62 countries as well as in the Mediterranean region and Iran (6-10). Previous studies showed that the etiological cause of kala-azar in Iran (Ardabil, Fars, East Azarbaijan, North Khorasan, Qom and Bushehr) is the L. infantum strain (11-16).
From a morphological point of view, Leishmania can be categorized into two forms, amastigote and promastigote. The axenic amastigotes (AxAs) type is culturable in vitro and requires conditions like macrophage phagolysosome for growth (17-22). Amastigotes, which are produced in this condition, are designated as axenic. Culturing axenic amastigotes is performed for most of the Leishmania species and shows successful outcomes (23-25). According to the reports, since the infectivity of macrophage by AxAs forms, such as amastigote forms, are greater than promastigotes (26) it seems that this form of parasite will be ideal form for production of monoclonal antibodies. Data reported by an investigation shows that while, no expression of amastin gene observed with promastigote of Leishmania, amastin gene could be selectively expressed by AxAs of L. tropica. Also, specific expression of amastin has been confirmed by RT-PCR using amastigote and AxAs. Moreover, this study has shown that cpb gene was only expressed by amastigotes and AxAs and not promastigotes. Therefore because there are strongly similarities between amastigotes and AxAs, it seems that AxAs has ability to be useful on preparation of monoclonal for differentiation of parasites as well as in purification of antigens and drug screening (26, 27). In addition, as we know the antigens of amastigotes are the first one presented to immunological system of the host. Therefore, axenic amastigotes type of L. infantum was used in this study for preparation of monoclonal antibody.
The infection fate in leishmaniasis depends on two important factors, the immunologic status of the host plus species and the strain of parasites. L. infantum causes a lethal disease called Kala-azar (28-30). Health programs have failed to control this disease and there is no efficient preventive vaccine. Therefore, treatment is the only way to counter this disease. The first step in the treatment is diagnosis of the parasite in an appropriate time, and its distinction from other diseases. Although there are some useful practical methods for the diagnosis of leishmaniasis, the sensitivity is still a problem. These methods have different sensitivities, some of which show low sensitivity and specificity. More specific methods such as monoclonal antibodies (mAbs) to develop an enzyme-linked immunosorbent assay (ELISA) method may be more convenient in a common laboratory. These antibodies are used as efficient tools in diagnostic, treatment and research approaches to recognize microorganism antigens (31-34). Herein, in this study we produced mAbs against AxAs form of Iranian L. infantum in order to design an ELISA kit in the future.
Materials and Methods
Culture of L. infantum strains (promastigotes and amastigotes forms): Promastigote culture
The Iranian strain of L. infantum (MHOM/IR/04/IPI-UN10) isolated from a patient and reference strain of WHO (MHOM/TN/80/IPT1) was used in this study. At first, promastigotes of these strains were cultured in NNN (Novy-MacNeal-Nicolle) special media. Then, the parasites were transferred to RPMI-1640 medium (Gibco, Germany), supplemented with fetal bovine serum (FBS) 10% (Biosera, UK), 2 mM L-glutamine (Gibco, Germany) penicillin (100 U/ml) and streptomycin (100 μg/ml) (Merck, Germany). They were incubated in 24°C to reach appropriate concentration. After that, the cultured promastigotes were used to obtain amastigotes like forms parasites.
Culture of axenic amastigote
Late logarithmic phase cultures of L. infantum promastigotes were transferred to RPMI-1640 medium supplemented with 25% FBS and incubated at 37 °C (5% CO2) for 16–24 hr. Thereafter, the cells were centrifuged (1200×g at room temperature for 10 min) and resuspended in the same medium supplemented with (10 mM) succinate (Merck, Germany), titrated to pH 5.5 and incubated as above. Under this situation, promastigotes differentiated to amastigotes like form (AxAs) within 120 hr and amastigote forms without flagellate were produced (31-33).
Preparation of AxAs L. infantum antigens
Harvested amastigotes were counted (4×109 parasite cells) and their antigens were extracted using the freeze (five times at liquid nitrogen) and thaw at 37º C. For preparation of antigens, different dilutions were prepared in several vials. Amastigotes antigens were collected and stored at -70 °C until use (31, 33).
Immunization of mice
Four female BALB/c (6-8 weeks old) mice were injected intraperitoneally, and subcutaneously (at tail base) with 40 µg of soluble AxAs L. infantum antigens preparation in complete Freund adjuvant and 2 weeks later were boosted with the same amount of antigen in incomplete Freund adjuvant. Then the serum antibody titers of mice 30 days after injection were measured. When 1/1000 dilution of sera had positive reaction with antigen in ELISA, the mouse with highest OD in ELISA was selected for fusion. Three days before fusion, selected mouse was boosted with 40 µg antigen intravenous through the tail (34-36). All experiments in this study performed according to Ethic Committee of Tehran University of Iran.
Extraction and collection of spleen cells
Three days after final immunization, mouse was sacrificed and the spleen of mouse was isolated aseptically. Using a 20 ml syringe containing RPMI medium and with needle tip 25, spleen cells were collected. This procedure was repeated several times until all spleen cells were drained. On the suspension, 5 ml of ammonium chloride was added and then centrifuged (2000 × g 10 min) to lyse erythrocytes.
Cell fusion
Sp2/0-Ag14 cells (IBRC C10106) were used for fusion and cultured in special medium. Several cultures of these cells were prepared and their growth rate was assessed precisely, and cultures with live cells higher than 90% were selected for fusion. The cells were kept in exponential growth phase and retained at this phase for fusion. Isolated lymphocytes from spleen of immunized mice and myeloma cells were fused at a ratio of 10 to 1 in the presence of PEG (polyethylene glycol; MW 1450, Sigma) and then fused cells were transferred to the complete culture medium containing HAT (hypoxanthine-aminopterin-thymidine) medium (Sigma, USA), 2%, L-glutamine (2 mM), 20% FBS, 5% CO2, 1% penicillin (100 U/ml) with streptomycin (100 μg/ml) and were incubated at 37 °C. After 1 week, HAT medium were replaced with HT (hypoxanthine and thymidine) medium (Sigma, USA). Hybridoma cell presence and the colonies were identified using an invert microscope. Part of these cells were suspended in a special freezing medium and reserved in liquid nitrogen for future tests. Also, some parts of them were used for subsequent analyses (34, 35).
Cloning of hybridoma cells by limiting dilution assay
Positive clones were selected. Each colon was suspended in culture medium using limiting dilution and split into 96-well plates to reach a uniform suspension so that approximately one cell was placed in each well and incubated at 37 °C. They were cultured in complete culture medium plates with feeder layer and supplements such as oxalate, pyruvate, and insulin like growth factor (Merck, Germany). Consequently, mAb producing monocolones were isolated.
Production of ascitic fluids
Hybridoma cells with (the highest OD) producing mAbs were grown in RPMI-1640 (Gibco) supplemented with 10% FBS, harvested and washed twice in phosphate-buffered saline (PBS), (Sigma). Eight days after pristane injection, BALB/c mice were injected intra-peritoneally with 2×106 hybridoma cells suspended in 0.5 ml PBS. Fluid was collected from the peritoneal cavity 10 days after the injection of the cells. Ascitic fluid was kept at 4 °C for 1 hr and centrifuged at (4000× g 20 min). Supernatant was collected and stored at -70 °C until use (34, 35).
Isotype determination
Two monoclones with higher OD were selected. The class and subclass of the mAbs were determined by ELISA with a mouse monoclonal sub isotyping kit containing rabbit anti-mouse IgG1, IgG2a, IgG2b and IgA (Sigma, USA).
SDS-PAGE and Western-immunoblotting
SDS-PAGE was performed according to the Laemmli method. Gels were stained with Coomassie Blue and later with silver staining. Proteins separated by SDS-PAGE were transferred to nitrocellulose sheets (Schleicher & Schuell, 0.45 μm pore size) by semi-dry blotting technique. Subsequently, the nitrocellulose sheet was incubated with 1% BSA in PBS buffer for 1 hr and then incubated with hybridoma culture supernatant at 4 °C overnight. The membrane was washed with PBS containing 0.1% BSA and 0.05% Tween 20, and second antibody (HRP-conjugated goat anti-mouse). After washing, the immune complex was detected by a color reaction using diaminobenzidine as enzyme substrate containing 0.03% COCl2 for color enhancement.
Diagnosis of L. infantum isolates by AxA monoclones
The mAb 8D2 FVI6 was used for diagnosis of L. infantum promastigotes isolated from three Kala-Azar patients using ELISA tests. The isolates, which was a gift from Dr Mohabali, (School of Public Health, Tehran), were coated at 96 well plates after freez-thaw, and followed by ELISA test.
Results
AxAs L. infantum antigen
Antigens 7×109 from AxAs L. infantum parasites were obtained, then optimal number of antigens for assessment of antibodies was determined using the ELISA method.
Comparison of antibody titer in immunized mice
In different fusion programme (12 times), five mice were used for immunization, the mouse with higher OD in ELISA was selected for fusion. For example in fusions 6 the mouse 3 with OD equal 2.43 were selected for fusion (Figure 1).
Figure 1.

Comparison of antibody titer in immunized mice. Mouse numbers 1 to 5 are immunized mice by antigen (AXA Leishmania infantum). The highest OD is seen in mice 3
Positive hybridomas with highest OD
After pre-screening of hybridomas, further analysis was performed by cloning and sub-cloning using limiting dilution. These sub-clones were investigated by ELISA, from third fusion: Subclones of 1A4 F III, 4B4 F III, 4G1 F III and 8E4 F III, from forth fusion: Subclones of ID6 FVI, 4C9 FIV, 6C4 FIV and 7F6 FIV, from fifth fusion: subclones of 8G8 FV, 8F4 FV, 8E6 FV and 6G2 FV and from sixth fusion: Subclones of 5G6 FVI, 5H10 FVI, 6G2 FVI and 8D2 FV hybridomas were isolated. Some of these hybridomas were reserved in liquid nitrogen for future analysis. Results are presented in Table 1.
Table 1.
Positive hybrids obtained from 4 fusions with highest OD
| Fusion III | Fusion V | Fusion IV | Fusion VI | ||||
|---|---|---|---|---|---|---|---|
| Hybrids | OD | Hybrids | OD | Hybrids | OD | Hybrids | OD |
| 1A4 F III | 0.719 | 6G2 FV | 0.819 | 1D6 FIV | 1.465 | 5G6 FVI | 1.163 |
| 4B4 F III | 0.745 | 8E6 FV | 0.801 | 4C9 FIV | 0.998 | 5H10 FVI | 1.107 |
| 4G1 F III | 0.748 | 8F4 FV | 0.850 | 6C4 FIV | 0.999 | 6G2 FVI | 1.192 |
| 8E4 F III | 0.692 | 8G8 FV | 0.858 | 7F6 FIV | 0.994 | 8D2 FVI | 1.515 |
(OD450) Absorbance of samples at 450 nm
Monoclones obtained by limiting dilution method
In this study, about 1850 hybridomas were screened in which 84 showed positive hybridomas. Among them, 25 monoclones were positive and of these sets 12 monoclones had acceptable optical absorbance. Finally, 4 of them (8D2 FVI6, 8D2 FVI3, 6G2 FV4 and 6G2 FV3) showed absorbance higher than 1 in ELISA test. From these hybrids, anti-amastigotes L. infantum mAbs were obtained. Among above-mentioned hybridomas, positive ones namely 6G2FV(OD=1.365) and 8D2FVI (OD=1.415), which showed the highest amount of produced antibody against L. infantum amastigotes were selected and after preparing homogenous suspension were diluted by limiting dilution method. As a result, mAbs producing monoclones were isolated. Table 2 shows the results of hybridoma proliferation for isolation of antibody producing monoclones using limiting dilution method.Two cases of these monoclones (6G2 FV2, 8D2 FVI6) were selected for isotype determination.
Table 2.
Results of hybridoma proliferation for isolation of antibody producing monoclones using limiting dilution method
| Hybrid(8D2 FVI) | Hybrid(6G2 FV) | ||||
|---|---|---|---|---|---|
| Monoclons | OD | Monoclons | OD | Monoclons | OD |
| 8D2 FVI6 | 1.510 | 6G2 FV6 | 0.889 | 6G2 FV10 | 0.777 |
| 8D2 FVI7 | 0.99 | 6G2 FV1 | 0.890 | 6G2 FV8 | 0.895 |
| 8D2 FVI1 | 0.880 | 6G2 FV7 | 0.900 | 6G2 FV2 | 1.410 |
| 8D2 FVI9 | 0.769 | 6G2 FV3 | 1.112 | 6G2 FV4 | 0.989 |
| 8D2 FVI10 | 0.567 | 6G2 FV5 | 0.899 | ||
| 8D2 FVI8 | 0.898 | 6G2 FV9 | 0.788 | ||
(OD450): Absorbance of samples at 450 nm
Class and sub-classes of mAbs
Classification of mAbs (6G2 FV2, 8D2 FVI6) showed that the produced mAbs against AxAs L. infantum in cell fusion belong to IgG class and IgG2b sub-class. Table 3 shows class and sub-classes of mAbs identified. Two monoclones with higher OD (6G2 FV2, 8D2 FVI6) were used for determination of class and sub-classes. Both of them showed class IgG and IgG2b subclass.
Table 3.
Class and sub-classes of mAbs identified
| mAbs | 8D2 FVI6 | 6G2 FV2 | ||||||
|---|---|---|---|---|---|---|---|---|
| Class | Anti mous IgG | Ig | Anti mous IgG | Ig | ||||
| sub-class | IgG1 | IgG 2a | IgG 2b | IgA | IgG 1 | IgG 2a | IgG 2b | IgA |
| OD | 0.11 | 0.143 | 1.685 | 0.12 | 0.128 | 0.114 | 1.781 | 0.111 |
| B | 0.012 | 0.023 | 0.043 | 0.011 | 0.076 | 0.089 | 0.079 | 0.059 |
(OD450): Absorbance of samples at 450 nm, B; Blank
The result of SDS-PAGE and Western blotting
To determine the specificities of mAb (8D2 FVI6), SDS-PAGE analysis was performed, followed by Western-blot analysis. As Figure 2 shows, Western blotting of monoclonal antibody (8D2 FVI6) confirms that this antibody has ability to recognize AxA L. infantum antigens.
Figure 2.

Western blotting of monoclonal antibody (8D2 FVI6). A sharp single band was seen in 30 kDa (shown by arrow). A: AxA Leishmania infantum antigens loaded, B: Promastigotes of Leishmania infantum antigens loaded
Identification of L. infantum isolates
The mAb 8D2 FVI6 was used for identification of L. infantum promastigotes isolated from Kala-Azar patients using ELISA tests. As shown in Tabal 4, this mAb has ability to recognize also promastigote of different isolates of L. infantum.
Table 4.
Identification of different isolates of Leishmania infantum (promastigotes) and AxAs of Leishmania infantum by mAb prepared from 8D2 FVI6
| Samples | Leishmania infantum isolates (Promastigote) | AxAs Leishmania infantum | PC | NC B | ||
|---|---|---|---|---|---|---|
| S1 | S2 | S3 | ||||
| OD | 0.526 | 0.802 | 0.795 | 1.250 | 2.519 | 0.069 0.034 |
PC: Positive control (Immunized mouse serum); NC: Negative control (Normal mouse serum); B: Blank (BSA); Dilute of immunized mouse posi-tive serum in wells:1/1000; (OD450) Absorbance of samples at 450 nm
Discussion
After mAbs discovery by Kohler and Milestein in 1975, there has been astonishing and fast progress in hybridoma technology and mAb application (36). In 1982, de Ibarra et al. produced mAbs, which are able to detect different species of leishmania (37).
In 1983, Greenblatt et al. developed a mAb that could act against L. major and showed reaction against other species of the parasite (38). During the past decades, specific mAb against Leishmania amazonensi, mexicana and donovani have been produced and applied in immunological diagnosis and taxonomic studies of Leishmania species (39-41). Regarding the limited number of studies carried out on preparation of monoclonal antibodies against antigens of Leishmania species, adequate information about the AxAs L. infantum antigens is not available. Also, there has been no investigation around the developing mAb against Iranian strain of L. infantum. Therefore, producing specific mAb against amastigote form of Iranian strain of L. infantum seems to be essential.
Since, the man and rodents are the main host for different species of Leishmania, and parasites are introduced themselves inside the macrophages as amastigote form, it seems that preparation of monoclonal antibodies against amastigote like parasite could be useful agent in process of leishmaniases diagnosis.
In this study, 25 positive monoclones were obtained and from which 12 monoclones showed acceptable titer of antibodies. Moreover, 4 of them (8D2 FVI6, 8D2 FVI3, 6G2 FV4 and 6G2 FV3) showed higher titer of antibody (OD >1) in ELISA test.
In the third fusion, from eight 96-well plates, only 6 positive hybrids were obtained. However, 4 hybrids (1A4 F III, 4G1 F III, 4B4 F III, and 7A6 F III) showed in primary study positive but in the reassessment, these 4 hybrids turned to negative with lower OD. It seems that this phenomenon happened because of chromosome instability in hybridoma cells (42).
According to Table 1, three fusions including fusion 4, 5 and 6 were ontained successfully. About 10% of each plate contained positive clones and this ratio seems to be acceptable. Clones with high absorbance in interaction with AxAs L. infantum were selected for proliferation using limiting dilution method and about 30% of wells were positive and monoclone. Hybrids with OD>1 (6G2 FV3, 6G2 FV4, 8D2 FVI3, 8D2 FVI6) were reserved in liquid nitrogen for future studies and probably kit development. 30% range is appropriate and coincides with a=e-b formula. This is Poisson’distribution and according to the Goding interpretation, if b=1, then “a” will be equal to 37. Therefore, if one cell is added to each well, it is probable that in minimum there are no cells in 37% of wells. Therefore, wells that cell proliferation is shown in them contain real mAbs (43, 44).
After limiting dilution performing and obtaining monoclones, class and sub-classes were identified. Clone 6G2FV2 was from IgG class and IgG2b sub-class (OD=1.685), and 8D2FVI6 clone was from IgG class and IgG2b sub-class (OD=1.781). The accuracy of the mAb (8D2 FVI6) was shown by Western blotting which shows that this antibody could recognize AxA L. infantum antigen at about 30 kDa area. There is inconsistency between our results and data reported by Debrabant et al., who have shown the band of axenic amastigote of L. donovani at about 40 kDa areas (45). The difference between two proteins may be attributed to the distinct strains has been used in analysis of both studies.
Diagnosis of L. infantum isolates by mAb (8D2 FVI6) was indicated that the mAb aginst AxA has ability to recognize different isolates of L. infantum.
Taken together, these mAbs have capacity to be used in Leishmania diagnostic kits and also for purification of antigen to be tested.
Conclusion
Hybridoma technologies can be used for the reliable development of mAbs and their subsequent production in different cells. In principle, the method has been widely applied in various fields such as diagnosis applications, disease monitoring and identifying prognostic markers (46-50). This study produced mAbs against amastigotes of Iranian strain of L. infantum for the first time. It seems that these antibodies have appropriate reactivity against Iranian strain of L. infantum and could be used in ELISA, immunofluorescence and flowcytometry tests for research and diagnosis (46-50). Taking into the account that the main resistance mechanism against leishmania parasite is cellular immunity, it is proposed that produced mAbs could be used to purify related antigens in axenic amastigotes and used to find a candidate molecule for vaccine studies. As well as identifying species using mAbs in areas where leishmaniasis is prevalent may be of great significance, however, it will be helpful for epidemiologic studies and important for treatment of travelers from non-endemic to endemic areas of leishmaniases including Iran. These antibodies may also provide help for the affinity purification of antigens or suitable targets for chemotherapeutic agents.
Acknowledgment
Immunology Department of Pasteur Institute of Iran, Microbiology Department, Cell and Molecular Biology Department of University of Tehran, Iran are appreciated for their technical support. The results described in this paper were part of student thesis. This work was supported by a research grant Immunology Department of Pasteur Institute of Iran (Grant No. 694).
References
- 1.Kennedy PJ, Oliveira C, Granja PL, Sarmento B. Monoclonal antibodies: Technologies for early discovery and engineering. Crit Rev Biotechnol. 2017;8:1–15. doi: 10.1080/07388551.2017.1357002. [DOI] [PubMed] [Google Scholar]
- 2.Ready PD. Epidemiology of visceral leishmaniasis. Clin Epidemiol. 2014;6:147–154. doi: 10.2147/CLEP.S44267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Bhattacharya SK, Dash AP. Treatment of visceral leishmaniasis: options and choice. Lancet Infect Dis. 2016;16:142–143. doi: 10.1016/S1473-3099(15)00528-9. [DOI] [PubMed] [Google Scholar]
- 4.Pezeshkpoor F, Rezaei AR, Shirdel A, Khajedaluee M, Alizadeh M, Yazdanpanah MJ. Association between HTLV-I infection with chronic lupoid Leishmaniasis. Iran J Basic Med Sci. 2013;16:281–283. [PMC free article] [PubMed] [Google Scholar]
- 5.Galgamuwa LS, Sumanasena B, Yatawara L, Wickramasinghe S, Iddawela D. Clinico-Epidemiological patterns of cutaneous Leishmaniasis patients attending the anuradhapura teaching hospital, Sri Lanka. Korean J Parasitol. 2017;55:1–7. doi: 10.3347/kjp.2017.55.1.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Heidari A, Mohebali M, Kabir K, arati H, Soultani Y, Keshavarz H, Akhoundi B, Hajjaran H, Reisi H. Visceral Leishmaniasis in rural areas of Alborz Province of Iran and implication to health policy. Korean J Parasitol. 2015;53:379–383. doi: 10.3347/kjp.2015.53.4.379. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Rajabi O, Sazgarnia A, Abbasi F, Layegh P. The activity of ozonated olive oil against leishmania major promastigotes. Iran J Basic Med Sci. 2015;18:915–919. [PMC free article] [PubMed] [Google Scholar]
- 8.Sayyahfar S, Ansari S, Mohebali M, Behnam B. Visceral Leishmaniasis without Fever in an 11-month-old infant: A rare clinical feature of Kala-azar. Korean J Parasitol. 2014;52:189–191. doi: 10.3347/kjp.2014.52.2.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Nadim A. Present status of kala-azar in Iran. Am J. Trop. Med. Hyg. 1978;27:25–28. doi: 10.4269/ajtmh.1978.27.25. [DOI] [PubMed] [Google Scholar]
- 10.Bettini S, Gradoni L. Canine leishmaniasis in the Mediterranean area and its implications for human leishmaniasis. Insect. Sci. Appl. 1986;7:241–245. [Google Scholar]
- 11.Mohebali M, Edrissian GH, Shirzadi MR, Akhoundi B, Hajjaran H, Zarei Z, Molaei S, Sharifi I, Mamishi S, Mahmoudvand H, Torabi V, Moshfe A, Malmasi A, Motazedian MH, Fakhar M. An observational study on the current distribution of visceral leishmaniasis in different geographical zones of Iran and implication to health policy. Travel Med Infect Dis. 2011;9:67–74. doi: 10.1016/j.tmaid.2011.02.003. [DOI] [PubMed] [Google Scholar]
- 12.Akhavan AA, Yaghoobi-Ershadi MR, Khamesipour A, Mirhendi H, Alimohammadian MH, Rassi Y, Arandian MH, Jafari R, Abdoli H, Shareghi N, Ghanei M, Jalali-zand N. Dynamics of Leishmania infection rates in Rhombomys opimus (Rodentia: Gerbillinae) population of an endemic focus of zoonotic cutaneous leishmaniasis in Iran. Bull Soc Pathol Exot. 2010;103:84–89. doi: 10.1007/s13149-010-0044-1. [DOI] [PubMed] [Google Scholar]
- 13.Farajnia S, Darbani B, Babaei H, Alimohammadian MH, Mahboudi F, Gavgani AM. Development and evaluation of Leishmania infantum rK26 ELISA for serodiagnosis of visceral leishmaniasis in Iran. Parasitology J. 2008;19:1–7. doi: 10.1017/S003118200800454X. [DOI] [PubMed] [Google Scholar]
- 14.Alimohammadian MH, Kivanjah M, Pak F, Gaznavi A, Kharazmi A. Evaluation of the efficacy of Iran leishmanin and comparison with leishmanins form Wellcome (UK) and Roma (Italy) in cured cutaneous leismaniasis patients. Trans R Soc Trop Med Hyg. 1993;87:550–551. doi: 10.1016/0035-9203(93)90083-3. [DOI] [PubMed] [Google Scholar]
- 15.Alimohammadian MH, Almasi H, Khabiri AR, Hatam GR, Karimi A, Mahboudi F, Tehrani SM, Amirkhani A. Identification of species and characterization of an outbreak of cutanous leishmaniasis in a new focus of Iran. Iran Biomed J. 1999;3:31–39. [Google Scholar]
- 16.Tashakori M, Ajdari S, Kariminia A, Mahboudi F, Alimohammadian MH. Chracterization of Leishmania species and L. major strains in different endemic areas of cutaneous leishmaniasis in Iran. Iran Biomed J. 2003;7:43–50. [Google Scholar]
- 17.Tavaresa J, Ouaissic BA, Lind PKT. Differential effects of polyamine derivative compounds against Leishmania infantum promastigotes and axenic amastigotes. Int J Parasitol. 2005;35:637–646. doi: 10.1016/j.ijpara.2005.01.008. [DOI] [PubMed] [Google Scholar]
- 18.Sereno D, Holzmuller P, Lemesre JL. Efficacy of sec line drugs on antimonyl-resistant amastigotes of Leishmania infantum. Acta Tropica. 2000;74:25–31. doi: 10.1016/s0001-706x(99)00048-0. [DOI] [PubMed] [Google Scholar]
- 19.Alain D, Manju BJ, Pimenta PFP, Dennis M D. Generation of Leishmania donovani axenic amastigotes: their growth and biological characteristics. Int J Parasitol. 2004;34:205–217. doi: 10.1016/j.ijpara.2003.10.011. [DOI] [PubMed] [Google Scholar]
- 20.Rochettea A, Raymond F, Corbeil J, Ouellette M, Papadopoulou B. Whole-genome comparative RNA expression profiling of axenic and intracellular amastigote forms of Leishmania infantum. Mol Biochem Parasitol. 2009;165:32–47. doi: 10.1016/j.molbiopara.2008.12.012. [DOI] [PubMed] [Google Scholar]
- 21.Herwldt BL. Leishmaniasis. Lancet. 1999;354:1191–1199. doi: 10.1016/S0140-6736(98)10178-2. [DOI] [PubMed] [Google Scholar]
- 22.Gupta N, Goyal N, Rastogi AK. In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends Parasitol. 2001;173:150–153. doi: 10.1016/s1471-4922(00)01811-0. [DOI] [PubMed] [Google Scholar]
- 23.Pan AA. Leishmania mexicana : Serial cultivation of intracellular stages in a cell-free medium. Exp Parasitol. 1984;58:72–80. doi: 10.1016/0014-4894(84)90022-5. [DOI] [PubMed] [Google Scholar]
- 24.Bates PA. Axenic culture of Leishmania amastigotes. Parasitol Today. 1993;9:143–146. doi: 10.1016/0169-4758(93)90181-e. [DOI] [PubMed] [Google Scholar]
- 25.Bates PA. Complete developmental cycle of Leishmania mexicanain axenic culture. Parasitology J. 1994;108:1–9. doi: 10.1017/s0031182000078458. [DOI] [PubMed] [Google Scholar]
- 26.Nasereddin A, Schweynochb C, Schonianb G, Jaffe JL. Characterization of Leishmania (Leishmania) tropica axenic amastigotes. Acta Tropica. 2010;113:72–79. doi: 10.1016/j.actatropica.2009.09.009. [DOI] [PubMed] [Google Scholar]
- 27.Sereno D, Cavaleyra M, Zemzoumi K, Maquaire S, Ouaissi A, Lemesre JL. Axenically grown amastigotes of Leishmania infantum used as an In vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother. 1998;42:3097–3102. doi: 10.1128/aac.42.12.3097. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kurtzhals JAL, Hey AS, Jardim A, Kemp M, Schaefer KU, Odera EO, Christensen CBV, Githure JI, Olafson RW, Theander TG, Kharazmi A. Dichotomi of the human T cell response to Leishmania antigens. II. Absent or Th2-like response to gp63 and Th1-like response to lipophosphoglycan-associated protein in cells from cured visceral leishmaniasis patients. Clin Exp Immunol. 1994;96:416–421. doi: 10.1111/j.1365-2249.1994.tb06044.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Zoghlami Z, Chouihi E, Barhoumi W, Dachraoui K, Massoudi N, Ben Helel K, Habboul Z, Hadhri MH, Limam S, Mhadhbi M, Gharbi M, Zhioua E. Interaction between canine and human visceral leishmaniases in a holoendemic focus of Central Tunisia. Acta Trop. 2014;139:32–38. doi: 10.1016/j.actatropica.2014.06.012. [DOI] [PubMed] [Google Scholar]
- 30.Savoia D. Recent updates and perspectives on leishmaniasis. J Inf Dev Ctries. 2015;96:588–596. doi: 10.3855/jidc.6833. [DOI] [PubMed] [Google Scholar]
- 31.Debrabant A1, Joshi MB, Pimenta PF, Dwyer DM. Generation of Leishmania donovani axenic amastigotes: Their growth and biological characteristics. Int J Parasitol. 2004;34:205–217. doi: 10.1016/j.ijpara.2003.10.011. [DOI] [PubMed] [Google Scholar]
- 32.Saar Y, Ransford A, Waldman E, Mazareb S, Amin-Spector S, Plumblee J, Turco SJ, Zilberstein D. Characterization of developmentally-regulated activities in axenic amastigotes of Leishmania donovani. Mol Biochem Parasitol. 1998;95:9–20. doi: 10.1016/s0166-6851(98)00062-0. [DOI] [PubMed] [Google Scholar]
- 33.Gupta N, Goyal N, Rastogi AK. In vitro cultivation and characterization of axenic amastigotes of Leishmania. Trends Parasitol. 2001;17:150–153. doi: 10.1016/s1471-4922(00)01811-0. [DOI] [PubMed] [Google Scholar]
- 34.Tomita M, Tsumoto K. Hybridoma technologies for antibody production. Immunotherapy. 2011;3:371–380. doi: 10.2217/imt.11.4. [DOI] [PubMed] [Google Scholar]
- 35.Moritaa M, Sugiharaa H, Tokunakaa K, Tomuraa A, Saigaa K, Satoa T, Imamurab Y, Hayashic T. Preparation and partial characterization of monoclonal antibodies specific for the nascent non-triple helical form of the type IV collagen alpha 1 chain. Biochem Biophys Rep. 2017;9:128–132. doi: 10.1016/j.bbrep.2016.11.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Kholer G, Milestine C. Continuous cultures of fused cells secreting antibody of predefined specificity. Natur. e1975;125:495–497. doi: 10.1038/256495a0. [DOI] [PubMed] [Google Scholar]
- 37.De Ibarra AA, Howard JG, Snary D. Monoclonal antibodies to Leishmania tropica major : specificities and antigen location. Parasitology J. 1982;85:523–531. doi: 10.1017/s0031182000056304. [DOI] [PubMed] [Google Scholar]
- 38.Greenblatt CL, Slutzky GM, De Ibarra AA, Snary D. Monoclonal antibodies for serotyping Leishmania strains. J Clin Microbiol. 1983;18:191–193. doi: 10.1128/jcm.18.1.191-193.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Chaves CS, Soares DC, Da Siva RP, Saraiva EM. Characterization of the species-and stage specificity of two monoclonal antibodies against Leishmania amazonensis. Exp. Parasitol. 2003;103:152–159. doi: 10.1016/s0014-4894(03)00098-5. [DOI] [PubMed] [Google Scholar]
- 40.York DS, Heinz S, Beatrice M, David GR, Margret Q, Peter O. Monoclonal antibodies to Leishmania mexicana promastigote antigen. J Cell Sci. 1991;99:181–186. doi: 10.1242/jcs.99.1.181. [DOI] [PubMed] [Google Scholar]
- 41.Mandira M, Anindita B, Swadesh D. Monoclonal antibody affinity purification of a 78 KDa membrane protein of Leishmania donovani of Indian origin and its role in host –parasite interaction. Indian Academy Science. 2002;27:665–672. doi: 10.1007/BF02708374. [DOI] [PubMed] [Google Scholar]
- 42.Goding JW. Monoclonal antibodies: Principles and practice? 2nd ed. Academic Press; 1986. Theory Monoclonal antibodies; pp. 5–58. [Google Scholar]
- 43.Macken C. Design and analysis of serial limiting dilution assays with small sample sizes. J Immunol Meth. 1999;222:13–29. doi: 10.1016/s0022-1759(98)00133-1. [DOI] [PubMed] [Google Scholar]
- 44.Galfre G, Howe SC, Milstein C, Butcher GW. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature. 1977;266:550–552. doi: 10.1038/266550a0. [DOI] [PubMed] [Google Scholar]
- 45.Debrabanta A, Joshib MB, Pimentac PFP, Dwyer DM. Generation of Leishmania donovani axenic amastigotes: Their growth and biological characteristics. Int J Parasitol. 2004;34:205–217. doi: 10.1016/j.ijpara.2003.10.011. [DOI] [PubMed] [Google Scholar]
- 46.Tomita M, Tsumoto K. Hybridoma technologies for antibody production.Immunotherapy. 2011;3:371–380. doi: 10.2217/imt.11.4. [DOI] [PubMed] [Google Scholar]
- 47.Tomita M, Tsumoto K. Recent advances in antigen-based generation of monoclonal antibodies. Curr Immunol Rev. 2010;6:56–61. [Google Scholar]
- 48.Pasqualini R, Arap W. Hybridoma-free generation of monoclonal antibodies. Proc Natl Acad Sci USA. 2004;101:257–259. doi: 10.1073/pnas.0305834101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Schmitz K, Geisslinger G, Tegeder I. Monoclonal antibodies in preclinical EAE models of multiple sclerosis: A systematic review. Int J Mol Sci. 2017;18:1–18. doi: 10.3390/ijms18091992. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Kivi G, Teesalu K, Parik J, Kontkar E, Ustav M J, Noodla L, et al. HybriFree: A robust and rapid method for the development of monoclonal antibodies from different host species. BMC Biotechnol. 2016;16:2. doi: 10.1186/s12896-016-0232-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
